{
  "docId": "019de073-9f6d-75d9-b724-0b887fde2468",
  "docSlug": "f957aa564e21bc93d4cc30c084ec8efa",
  "documentTitle": "Aldeyra Therapeutics | Results Presentation Deck | 13 slides",
  "authorId": "aldeyra-therapeutics",
  "authorName": "Aldeyra Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 13,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "thesis_headline",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a faint background image of a vial and syringe.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9f6d-75d9-b724-0b887fde2468/4",
  "deckHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468",
  "deckJsonHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468.json",
  "deckAnchorHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "ADX-2191, if approved, will be the first cGMP manufactured methotrexate drug product for intravitreal administration.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f4333a7-2307-4b68-ba85-6a7df52ad21e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "The ADX-2191 intravitreal formulation is designed to be vitreous-compatible and optimized for excipient composition, viscosity, density, tonicity, pH, active ingredient concentration, and volume of administration.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2685fcfe-2899-4e12-a792-92008a4d15f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "list",
      "text": "ADX-2191 has received U.S. FDA Orphan Drug Designation for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and retinitis pigmentosa.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75ef054d-a45c-481d-a083-b7b0e2346bc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "ADX-2191 (methotrexate injection, USP) is the first sterile, non-compounded formulation of methotrexate designed to meet the unique requirements of intravitreal administration for specific rare retinal diseases, including primary vitreoretinal lymphoma and proliferative vitreoretinopathy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88bf2232-fa0f-4e2f-a440-9a296226a634",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "USP = United States Pharmacopeia; cGMP = current good manufacturing practices. ADX-2191 (methotrexate injection, USP) for intravitreal administration is an investigational drug candidate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87619245-9d78-40d6-812f-c8db74dfaa39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "ADX-2191, an Investigational Vitreous-Compatible Formulation of Methotrexate, Represents a Platform Approach for Rare Retinal Diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac0d699f-ac1a-450b-9d15-d70803437eeb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 3,
      "beatId": "f675744a-c5ea-4ba2-b7c3-2d862c0c6fae",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents ADX-2191 as a novel therapeutic option for PVR",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 4,
      "from": 4,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "26f7e659-e316-44f5-bb6d-9796a66f86d8",
      "evidence": "The document presents ADX-2191 as a solution to unmet needs in PVR treatment",
      "position": 1,
      "objective": "What are the unmet needs in PVR treatment?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}